MedTrace Logo

Phase I Study of QLS1510 Tablets in Healthy Participants

NCT07760077 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-08-12

No results posted yet for this study

Summary

This is a Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QLS1510 in Healthy participants

Conditions

  • Inflammatory Bowel Disease (IBD)

Interventions

DRUG

QLS1510 Tablets

Oral (swallow)

DRUG

QLS1510 placebo Tablets

Oral (swallow)

Sponsors & Collaborators

  • Shanghai Qilu Pharmaceutical Research and Development Center LTD

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-30
Primary Completion
2027-01-30
Completion
2027-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07760077 on ClinicalTrials.gov